Today: 7 February 2026
Subscribe
Browse Category

Stock Market News 30 December 2025

SoFi stock today: SOFI barely moves after Fed minutes; what investors watch next

SoFi stock today: SOFI barely moves after Fed minutes; what investors watch next

NEW YORK, December 30, 2025, 3:01 PM ET — Regular session SoFi Technologies, Inc. shares were down 0.1% at $26.80 on Tuesday afternoon, after trading between $26.65 and $27.14. The Federal Reserve released minutes from its Dec. 9–10 meeting at 2:00 p.m. ET, putting fresh attention on how quickly policymakers might cut interest rates again. Federal Reserve That matters for SoFi because investors tend to treat the fintech lender as sensitive to shifts in borrowing costs, which can influence consumer demand for loans and a lender’s funding expenses. Trading across Wall Street was choppy in a holiday-shortened week, with investors
30 December 2025
··
Why Western Digital stock is down today: WDC slides as year-end rotation cools AI-hardware trades

Why Western Digital stock is down today: WDC slides as year-end rotation cools AI-hardware trades

NEW YORK, December 30, 2025, 3:00 PM ET — Regular session Western Digital Corp shares fell 1.7% to $176.55 on Tuesday, after opening higher and sliding through the afternoon. The stock touched $181.34 earlier in the session before dipping as low as $176.31. The pullback lands after a standout year for the data-storage maker, whose shares have surged about 303% in 2025, making it one of the S&P 500’s biggest gainers. That steep run has made the stock a frequent target for late-December portfolio reshuffling. Barron’s Broader U.S. indexes were little changed in choppy, light-volume trading, with investors repositioning inside
30 December 2025
···
Carvana stock drifts in thin trade after Fed minutes — what CVNA investors are watching

Carvana stock drifts in thin trade after Fed minutes — what CVNA investors are watching

NEW YORK, December 30, 2025, 14:52 ET — Regular session Carvana Co shares edged lower on Tuesday afternoon, trading down less than 0.1% at $433.32, as year-end portfolio shifts kept risk appetite uneven across consumer names. The muted move matters because Carvana has become a high-beta momentum stock after a sharp turnaround, and thin holiday volumes can exaggerate day-to-day swings even when headlines are light. Investors also had fresh Federal Reserve minutes to digest. Rate expectations matter for used-car demand because financing costs influence monthly payments, a key factor for many buyers. Broader U.S. markets were subdued in choppy trading,
30 December 2025
····
Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

NEW YORK, December 30, 2025, 14:50 ET — Regular session Shares of lululemon athletica inc. fell about 0.6% to $211.30 in afternoon trading on Tuesday after founder Chip Wilson launched a proxy fight — a campaign to win shareholder votes for board seats — seeking to reshape the board. The stock had gained about 2% on Monday, Reuters reported. Reuters The board fight comes as the athletic apparel maker searches for a permanent chief executive after Calvin McDonald said he would step down on Jan. 31. Chief financial officer Meghan Frank and chief commercial officer André Maestrini are set to
30 December 2025
·
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

NEW YORK, December 30, 2025, 14:40 ET — Regular session Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance An NDA is the formal request asking the FDA to review a drug for marketing approval, a key inflection point for development-stage biotechs with no products on the market. U.S. Food and Drug Administration Systemic mastocytosis is a rare disorder marked by abnormal accumulation and activation of mast cells — immune
30 December 2025
··
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key swing factors for the stock heading into 2026. Biotech stocks lagged, with the iShares Nasdaq Biotechnology ETF down about 1.1%, while the healthcare sector ETF was roughly flat and the S&P 500 ETF hovered near unchanged. Verastem Oncology said it
30 December 2025
··
Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

NEW YORK, December 30, 2025, 14:44 ET — Regular session Texas Instruments Incorporated (TXN) shares were little changed on Tuesday after memory developer Weebit Nano said it had licensed its resistive random access memory, or ReRAM, technology to the chipmaker. The stock was down about 0.01% at $175.67 in afternoon trade, and TI executive Amichai Ron said the partnership would give customers access to “industry-leading NVM technology.” Weebit The announcement matters because embedded non-volatile memory — storage that keeps data when power is off — is a key building block for chips that run cars, factory equipment and other electronics
30 December 2025
··
Mastercard stock dips in thin year-end trade as Fed minutes sharpen rate focus

Mastercard stock dips in thin year-end trade as Fed minutes sharpen rate focus

NEW YORK, December 30, 2025, 14:45 ET — Regular session Mastercard Incorporated shares were down 0.3% at $576.37 in afternoon trading on Tuesday, after moving between $574.55 and $579.49 earlier in the session. Volume was about 683,000 shares. The small move still matters into year-end because investors use card networks as a bellwether for consumer spending. Mastercard earns fees when transactions run across its network, so shifts in shopping and travel can show up quickly in volume trends. Rates are also front and center for the group. Payment processors trade like high-quality growth stocks inside financials, which can make them
30 December 2025
···
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters for Arcutis because it trades as a growth story tied to one product franchise, leaving the stock prone to outsized moves when sentiment sours across biotech and high-multiple names. Arcutis is a commercial-stage medical dermatology company whose main product, Zoryve
30 December 2025
·
Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

NEW YORK, December 30, 2025, 14:33 ET — Regular session Accenture plc shares were down about 0.5% on Tuesday, drifting lower in a quiet year-end session after Argus lowered its price target on the IT services company while maintaining a buy rating. The move matters because Accenture is widely treated as a read-through on corporate technology spending, and late-December liquidity is thin. In that backdrop, even routine changes in analyst targets can move large-cap consulting names more than usual. Traders were also navigating a fresh macro signal after Federal Reserve meeting minutes showed policymakers split over how quickly to keep
30 December 2025
·
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

NEW YORK, December 30, 2025, 2:26 PM ET — Regular session Vera Therapeutics, Inc. shares slid 3.4% to $50.45 in afternoon trading on Tuesday, giving back some recent gains as biotech stocks softened late in the year. The move matters now because Vera has become a bellwether “event-driven” biotech name, where day-to-day trading can swing sharply as investors calibrate risk around FDA timelines and competitive positioning in kidney disease. Thin year-end liquidity can amplify those swings, and traders have been quick to trim exposure to smaller, higher-beta healthcare names when the sector loses momentum. Minutes from the Federal Reserve’s December
30 December 2025
··
Rigetti stock today: RGTI steadies as Fed minutes and year-end flows keep quantum names jumpy

Rigetti stock today: RGTI steadies as Fed minutes and year-end flows keep quantum names jumpy

NEW YORK, December 30, 2025, 14:34 ET — Regular session Rigetti Computing shares edged up 0.3% to $22.34 on Tuesday afternoon, after swinging about 3% between the day’s high and low. IonQ rose 1.2% and D-Wave Quantum gained 1.6%. The muted move matters because quantum-computing stocks have become a high-beta pocket of the market, prone to sudden swings when liquidity thins and rate expectations shift. With the calendar turning, traders are re-pricing how much room the Federal Reserve has to ease in 2026. U.S. stocks were subdued in holiday-thin trading, with investors rotating within technology after a late-year run-up, Reuters
30 December 2025
·····
Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

NEW YORK, December 30, 2025, 2:20 PM ET — Regular session Shares of Ares Management Corp fell 3.1% to $163.85 in afternoon trading on Tuesday, down $5.20 from Monday’s close. The stock traded between $168.99 and $163.49, with about 966,000 shares changing hands. The move matters because Ares is closely tied to credit-market conditions. Investors are weighing where interest rates settle in early 2026 and what that means for fundraising, deal activity and returns in private credit. A Reuters Breakingviews column said private credit is losing some of its pricing edge as bank-led bond and loan markets regain momentum, pushing
30 December 2025
··
AT&T stock today ticks higher as Fed minutes loom and year-end rotation lifts telecoms

AT&T stock today ticks higher as Fed minutes loom and year-end rotation lifts telecoms

NEW YORK, December 30, 2025, 14:35 ET — Regular session AT&T Inc shares were up 0.1% at $24.80 in afternoon trade on Tuesday, hovering near the top of a tight day range as the broader market struggled for direction. The stock traded between $24.75 and $24.85. The move matters because income-heavy telecom stocks often trade with interest-rate expectations at year-end, when many investors rebalance portfolios. The yield on the 10-year U.S. Treasury note rose 1.8 basis points — a basis point is 0.01 percentage point — to 4.134%, and traders were awaiting the Federal Reserve’s meeting minutes later in the
30 December 2025
·····
PayPal stock slips in late trade after Fed minutes; here’s what PYPL investors are watching next

PayPal stock slips in late trade after Fed minutes; here’s what PYPL investors are watching next

NEW YORK, December 30, 2025, 14:33 ET — Regular session PayPal Holdings (PYPL.O) shares were down about 0.6% at $59.14 in afternoon trading on Tuesday, after the Federal Reserve’s latest meeting minutes sharpened the debate over where interest rates go next. The move matters because liquidity is thin into year-end, when smaller trades can have an outsized impact on price. For consumer-facing fintech names like PayPal, rate expectations and spending signals can quickly swing sentiment. Investors are also recalibrating for 2026 after fresh color from the Fed on how comfortable policymakers are with further easing. The minutes are a detailed
30 December 2025
··
IonQ stock rises today after South Korea seals 100-qubit quantum system deal

IonQ stock rises today after South Korea seals 100-qubit quantum system deal

NEW YORK, December 30, 2025, 14:31 ET — Regular session IonQ, Inc. shares were up 1.3% at $45.83 in regular trading on Tuesday after the company said it finalized an agreement to deliver a 100-qubit Tempo quantum system to South Korea’s Korea Institute of Science and Technology Information (KISTI). The stock has traded between $45.48 and $47.40, with volume around 9.3 million shares. IonQ said the system will be integrated into KISTI-6 “HANGANG,” a high-performance computing (HPC) cluster, in what it described as the country’s first on-site hybrid quantum-classical setup; CEO Niccolo de Masi called the deal “a defining moment
30 December 2025
··
Freeport-McMoRan stock today: FCX edges up as copper rebounds toward record highs

Freeport-McMoRan stock today: FCX edges up as copper rebounds toward record highs

NEW YORK, December 30, 2025, 2:22 PM ET — Regular session Freeport-McMoRan shares rose about 0.5% to $51.75 in afternoon trading on Tuesday, after swinging between $50.87 and $52.67 earlier in the session. The move matters because Freeport’s earnings tend to track copper prices closely. When the metal rises, miners typically see higher revenue per pound sold, which can lift cash generation. Copper’s year-end rally has put the spotlight back on supply tightness and demand tied to electrification and the buildout of power-hungry data centers. That backdrop has helped keep interest in large, liquid copper names such as Freeport. U.S.
30 December 2025
··
Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

NEW YORK, December 30, 2025, 14:21 ET — Regular session Karman Holdings Inc. shares were down 3.6% at $74.81 in afternoon trading on Tuesday, after touching $74.21 at the session low. The stock traded as high as $78.55, with about 465,000 shares changing hands. The dip comes in the final week of the year, when thinner liquidity can exaggerate moves in individual stocks. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide, in a broader market note on holiday-thin trading. Fund flows have also become a near-term
30 December 2025
··
CRH stock dips today as buyback rolls on and Fed minutes loom

CRH stock dips today as buyback rolls on and Fed minutes loom

NEW YORK, December 30, 2025, 14:02 ET — Regular session Shares of CRH plc (CRH) fell about 1.1% to $126.01 in afternoon New York trading on Tuesday after the building materials group disclosed another day of repurchases under its U.S. buyback program. CRH said it bought 31,100 shares on Monday at a volume-weighted average price of $127.33, paying between $126.46 and $128.87, and will cancel the shares as part of a plan to repurchase up to $300 million of stock by Feb. 17. The stock traded between $125.92 and $127.25 on Tuesday. Business Wire The move matters now because CRH
30 December 2025
·
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

NEW YORK, December 30, 2025, 02:05 PM ET — Regular session Zenas BioPharma Inc shares fell $2.02, or 5.2%, to $37.03 in afternoon trading on Tuesday, after ending the prior session at $39.05. The stock ranged from $36.94 to $40.50, with about 123,000 shares traded. The drop came as biotech stocks eased in thin year-end trading, with the Nasdaq Biotechnology Index down about 1%. That matters now because smaller, cash-burning drug developers often move with risk appetite as much as on headlines. indexes.nasdaqomx.com Wall Street’s main indexes were largely muted as investors waited for minutes from the Federal Reserve’s December
30 December 2025
··
1 … 555 556 557 558 559 … 1,170

Stock Market Today

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
New York, Feb 7, 2026, 11:29 ET — Market closed. AbbVie shares closed up 2% on Friday at $223.43, extending a second straight session of gains as U.S. stocks rallied. The stock is still roughly 9% below its 52-week high, and trading volume ran a bit under its recent average. (MarketWatch) The bounce comes as investors work through AbbVie’s post-earnings reset and what it means for 2026. The drugmaker said fourth-quarter net revenues rose 10% to $16.618 billion and adjusted profit per share—excluding certain items—was $2.71; it forecast 2026 adjusted earnings of $14.37 to $14.57 a share. Chief Executive Robert
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

7 February 2026
Bank of America shares rose 2.89% Friday to $56.53, tracking a rally in U.S. financial stocks as the Dow closed above 50,000. The bank will redeem its Series DD preferred stock and related depositary shares on March 10 at $1,000 per share. CEO Brian Moynihan donated 100,000 shares on Feb. 4, a regulatory filing showed. Key U.S. jobs and inflation data are due next week after delays.
Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

7 February 2026
Oracle shares jumped 4.65% to $142.82 Friday, ending an eight-day slide but remaining down 22% since Jan. 27. The company has set up a $20 billion at-the-market stock program and completed a $25 billion senior notes sale to fund cloud expansion. Oracle’s liabilities stood at $174.5 billion as of Nov. 30, 2025, before the new financing. Investors remain focused on dilution risks and the pace of capacity growth.
Go toTop